A recently approved twice-yearly injection to prevent HIV may warrant a higher price, but thousands of dollars more?  CVS Caremark’s chief medical officer calls on Gilead Sciences to lower the $28,000 ...
Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...
Among patients with late diagnosed HIV infection, the choice of a two- or three-drug regimen is not associated with 48 week ...
A new analysis finds that generic lenacapavir, a twice-yearly HIV preventive treatment, could be mass produced for just $25 ...
ScienceAlert on MSN
HIV's Cunning Strategy For Hiding in Our Body Finally Revealed
According to the new study, HIV achieves this with a tissue-specific approach, cloaking itself in a host cell's DNA by ...
Currently available medications could be enough to end the HIV epidemic in the United States, provided people can access and ...
Gilead Sciences (NASDAQ:GILD) has discontinued a Phase 1 trial for GS-1219, a long-acting subcutaneously delivered treatment ...
The American South has the highest HIV rates in the country, accounting for more than half of new HIV diagnoses nationwide in ...
Funding cuts for research intended to make treatment and cures available and accessible for patients with HIV could affect HIV care in the long term.
Cuts proposed by the Trump administration and House Republicans could drive up new HIV cases by more than 200,000 by 2030, ...
South Africa has welcomed a U.S. bridging plan worth $115 million to continue funding HIV treatment and prevention programs ...
MANILA: The World Health Organisation (WHO) in the Western Pacific region has raised alarm about the "sharp increases" in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback